

PROBLEM



Aging is bad, solutions locked

- Aging drives diseases and death
- The FDA doesn't recognize aging
- \$1B+, 10+ years for approval
- Sliver tsunami incoming





Charlatan Stem Cell Market


- Stem cell therapy grey market \$18B
- 100K+ treated annually
- Fragmented, unverifiable, no standards, mostly fraudulent





PERFECT STORM




Secretomes show incredible promise for life extension









DeSci as the next frontier of crypto



Regulatory revolution, startup cities, expanded right-to-try





INFINITA

ANTI AGING THERAPY



Research Lab



UNIVERSITY

Stem cells Neuroregeneration

Bioproduction Partner



Qualified labs in Haifa High yield cell line Anti-inflammatory cell secretome derived from Mesenchymal Stem Cells, administered intranasally




Targets biological aging


Excellent safety profile


Our Data


Reverses senescence Improves memory Neurogenesis (shown)

ed Naive me secretome









CLINICAL TRIAL



Aging Endpoint



LinAge2

Measure aging, not diseases
Based on blood markers
Clinically validated

Data Moat

Real data, not anecdotes

Transparency = Credibility

Priciple Investigator



Prof. Brian Kennedy,
Director, Centre for Healthy
Longevity, NUS

Trial Site




Decentralized Medical Committee

From multiple jurisdictions

MARKETING STRATEGY: TOKENIZATION



- > Memes drive virality and unlock scalable funding
- > Tokens align incentives for patients, clinics, and contributors
- > Token-gated priority access to treatments
- > Seamless shared ownership and coordination



MARKET



Anti Aging Medicine

- Positioned for cash-pay longevity clinics and wellness networks
- Builds data onramp for expansion into chronic conditions

Age Related Diseases

- Disease modifying potential for e.g.
 Alzheimer's, cardiovascular
- Huge unmet need, no effective treatments

TAM: \$300B

SAM: \$20B

SOM: \$2B

Annual sales



\$75M (23')



\$24M (22')



\$18M (21')

BUSINESS MODEL



Day8 Program = 8 days program

1 administration every day for 8 days, recurrent Cost: \$8,000 USDC

Sales to Premium Clinics

Year 1: 10 Clinics x 100 treatments per year X \$8K = \$8,000,000 revenue

IP Sublicensing to Strategic Partners

Leverage clinical-grade data to sublicense to larger pharma or wellness companies

Token Trading Fees

For continual replenishment of the treasury

Leverage Medical Innovation Jurisdictions Worldwide



Established ties in Malaysia, Thailand, Prospera, Oman, Germany

TEAM






Asher Raziel, Co-founder, CEO

Biotech operator, crypto native. American-Israeli. Raised VC funding for gene therapy biomanufacturing startup and personal bioreactor startup. Setup Phase 1 gene therapy trial in Prospera in 2021. BIO Protocol contributor. Duke uni BSc.



Tomer Landsberger, Co-founder, CSO

Israeli comp bio, PhD Immunology Weizmann Institute, Physics MSc, Philosophy MA. Ex Gero.ai, VitaDAO dealflow, Michael Levin's lab. Founded Sciborg. Deeply integrated into the longevity ecosystem. Spent the last two years living in pop-up cities around the world. Transhumanist.



Shay Geula, Head of R&D

Stem Cell & Aging Scientist. PhD Weizmann Institute, post-doc University of Texas. Cofounder of CatchMe Therapeutics & Renewal Bio, pioneering RNA-based therapeutics and innovative cell therapy solutions.



Gadi Turgeman, CAB

PI at Ariel University with 20 years' cell-biology experience; investigates mesenchymal stem cells, extracellular vesicles, and adult neurogenesis to develop therapies for neurobehavioral disorders and brain aging, including a current US-Israel BSF project on EVs for brain aging.

TRACTION



- Recruited KOL Brian Kennedy from National University of Singapore to sponsor trial
- > 2 year research program developing flagship anti aging product at Ariel University
- Negotiating partnership with NurExone for product production
- > Onboarded with BIO.xyz for token launch









ROADMAP



